Fibrate and statine myopathy;Fibrat-/statin-myopathie

Nervenarzt

Volumn 74, Issue 2, 2003, Pages 115-122

  Finsterer, J ^a  

^a KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

Author keywords

Lipid lowering drugs; Myopathy; Neuromuscular disorders; Rhabdomyolysis; Side effects

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; AZITHROMYCIN; BEZAFIBRAT; BEZAFIBRATE; CERIVASTATIN; CHLORZOXAZONE; CIPROFIBRATE; CLARITHROMYCIN; CLOFIBRATE; CYTOCHROME P450 INHIBITOR; DIGOXIN; DILTIAZEM; ERYTHROMYCIN; ETOFYLLINE CLOFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; ITRACONAZOLE; KETOCONAZOLE; LIPCOR; MEVINOLIN; MIBEFRADIL; NICOTINIC ACID; NORFLOXACIN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SELIPRAN; SIMVASTATIN; UNINDEXED DRUG;

ARTERIOSCLEROSIS; DERMATOMYOSITIS; DOSE RESPONSE; DRUG WITHDRAWAL; HUMAN; HYPOTHYROIDISM; KIDNEY FAILURE; MUSCLE RIGIDITY; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; MYOSITIS; POLYMYOSITIS; REVIEW; RHABDOMYOLYSIS; THROMBOEMBOLISM; URINE COLOR;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIAS; NEUROMUSCULAR DISEASES; PROPIONATES; RHABDOMYOLYSIS; RISK FACTORS;

EID: 0038476253     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-002-1445-6     Document Type: Review

References (79)

1. Al Shohaib S (2000) Simvastatin-induced rhabdomyolysis in a patient with chronic renal failure. Am J Nephrol 20:212-213
2. Berger O, Zifko U, Jellinger K, Machacek E, Grisold W (1993) Necrotizing myopathy with antilipemic agents. Case report and review of the literature. Nervenarzt 64:539-544
3. Bruckert E (2002) New advances in lipid-modifying therapies for reducing cardiovascular risk. Cardiology 97:59-66
4. Davidson MH (2001) Treatment of the elderly with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors: focus on drug interactions. J Cardiovasc Pharmacol Ther 6:219-229
5. Davignon J (1998) Advances in drug treatment of dyslipidemia: focus on atorvastatin. Can J Cardiol 14 [Suppl B]:28-38
6. England JD, Walsh JC, Stewart P, Boyd I, Rohan A, Halmagyi GM (1995) Mitochondrial myopathy developing on treatment with the HMG CoA reductase inhibitors simvastatin and pravastatin. Aust N Z J Med 25:374-375
7. Gabay M, Lodolce A (2001) Other reports of cerivastatin-induced rhabdomyolysis. Arch Intern Med 161:2629
8. Gagne C, Gaudet D, Bruckert E (2002) Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 105:2469-2475
9. Hamilton-Craig I. (2001) Statin-associated myopathy. Med J Aust 175:486-489
10. Heinonen TM (2002) Inhibition of acyl coenzyme A-cholesterol acyltransferase: a possible treatment of atherosclerosis? Curr Atheroscler Rep 4:65-70
11. Hodel C (2002) Myopathy and rhabdomyolysis with lipid-lowering drugs. Toxicol Lett 128:159-168
12. Hyman DJ, Henry A, Taylor A (2002) Severe rhabdomyolysis related to cerivastatin without gemfibrozil. Ann Intern Med 137:74
13. Igel M, Sudhop T, von Bergmann K (2001) Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins). Eur J Clin Pharmacol 57:357-364
14. Kashyap ML, McGovern ME, Berra K et al. (2002) Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol 89:672-678
15. Kyrklund C, Backman JT, Kivisto KT, Neuvonen M, Laitila J, Neuvonen PJ (2001) Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther 69:340-345
16. Langer T, Levy RI (1968) Acute muscular syndrome associated with administration of clofibrate. N Engl J Med 279:856-858
17. Laufs U, Gertz K, Dirnagl U, Bohm M, Nickenig G, Endres M (2002) Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res 942:23-30
18. Liamis G, Kakafika A, Bairaktari E et al. (2002) Combined treatment with fibrates and small doses of atorvastatin in patients with mixed hyperlipidemia. Curr Med Res Opin 18:125-128
19. Moghadasian MH, Mancini GB, Frohlich JJ (2000) Pharmacotherapy of hypercholesterolaemia: statins in clinical practice. Expert Opin Pharmacother 1:683-695
20. Moghadasian MH (1999) Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Life Sci 65:1329-1337
21. Murdock DK, Murdock AK, Murdock RW et al. (1999) Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders. Am Heart J 138:151-155
22. Oldemeyer JB, Lund RJ, Koch M, Meares AJ, Dunlay R (2000) Rhabdomyolysis and acute renal failure after changing statin-fibrate combinations. Cardiology 94:127-128
23. Olsson AG, Pears J, McKellar J, Mizan J, Raza A (2001) Effect of Rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol 88:504-508
24. Omar MA, Wilson JP, Cox TS (2001) Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 35:1096-1107
25. Paoletti R, Corsini A, Bellosta S (2002) Pharmacological interactions of statins. Atheroscler [Suppl 3]:35-40
26. Pfeffer MA, Keech A, Sacks FM et al. (2002) Safety and tolerability of pravastatin in long-term clinical trials: prospective pravastatin pooling (PPP) project. Circulation 105:2341-2346
27. Shek A, Ferrill MJ (2001) Statin-fibrate combination therapy. Ann Pharmacother 35:908-917
28. Sinzinger H, Laimer H, Hoppichler F et al. (2002) Fünf goldene Regeln. Statine ein Jahr danach. Österr Ärztezeitung 12/25 Juni 38-39
29. Stein EA (2002) Managing dyslipidemia in the high-risk patient. Am J Cardiol 89:50C-57C
30. Tomlinson B, Chan P, Lan IW (2001) How well tolerated are lipid-lowering drugs? Drugs Aging 18:66S-683
31. Tomlinson B, Lan IW (2001) Combination therapy with cerivastatin and gemfibrozil causing rhabdomyolysis: is the interaction predictable? Am J Med 110:669-670
32. Warren JD, Blumbergs PC, Thompson PD (2002) Rhabdomyolysis: a review. Muscle Nerve 25:332-347
33. Williams D, Feely J (2002) Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 41:343-370
34. Rumpf KW, Quellhrost E, Scheler F (1976) Diabetic nephropathy, hypothyroidism and colfibrate-induced myopathy. Med Klin 71:2023-2027
35. Rumpf KW, Barth M, Blech M, Kaiser H, Koop I, Arnold R, Scheler F (1984) Bezafibrate-induced myolysis and myoglobinuria in patients with impaired renal function. Klin Wochenschr 62:346-348
36. Garnett WR (1995) Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am J Health Syst Pharm 52:1639-1645
37. Baglin A, Lasserre N, Prinseau J, Lebas M (1987) Rhabdomyolysis under treatment by ciprofibrate in the nephrotic syndrome. Therapie 42:247-248
38. Denizot M, Fabre J, Pometta D, Wildi E (1973) Clofibrate, nephrotic syndrome, and histological changes in muscle. Lancet 1:1326
39. Pierides AM, Alvarez-Ude F, Kerr DN (1975) Clofibrate-induced muscle damage in patients with chronic renal failure. Lancet 2:1279-1282
40. Rimon D, Ludatscher R, Cohen L (1984) Clofibrate-induced muscular syndrome. Case report with ultrastructural findings and review of the literature. Isr J Med Sci 20:1082-1086
41. Chow LT, Chow WH (1994) Gemfibrozil induced myositis: a case report with light microscopic and ultrastructural study. Chin Med Sci J 9:129-131
42. Gorriz JL, Sancho A, Lopez-Martin JM, Alcoy E, Catalan C, Pallardo LM (1996) Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy. Nephron 74:437-438
43. Biesenbach G, Janko O, Stuby U, Zazgornik J (1996) Myoglobinuric renal failure due to long-standing lovastatin therapy in a patient with pre-existing chronic renal insufficiency. Nephrol Dial Transplant 11:2059-2060
44. Raimondeau J, Le Marec H, Chevallier JC, Bouhour JB (1992) Biological myolysis during combined fenofibrate-pravastatin therapy. Presse Med 21:663-664
45. Duell PB, Connor WE, Illingworth DR (1998) Rhabdomyolysis after taking atorvastatin with gemfibrozil. Am J Cardiol 81:368-369
46. Bermingham RP, Whitsitt TB, Smart ML, Nowak DP, Scalley RD (2000) Rhabdomyolysis in a patient receiving the combination of cerivastatin and gemfibrozil. Am J Health Syst Pharm 57:461-464
47. Ozdemir O, Boran M, Gokce V, Uzun Y, Kocak B, Korkmaz S (2000) A case with severe rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy - a case report. Angiology 51:695-697
48. Pogson GW, Kindred LH, Carper BG (1999) Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy. Am J Cardiol 83:1146
49. Lau TK, Leachman DR, Lufschanowski R (2001) Severe rhabdomyolysis associated with the cerivastin-gemfibrozil combination therapy: report of a case. Tex Heart Inst J 28:142-145
50. Glueck CJ, Oakes N, Speirs J, Tracy T, Lang J (1992) Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias. Am J Cardiol 70:1-9
51. Kogan AD, Orenstein S (1990) Lovastatin-induced acute rhabdomyolysis. Postgrad Med J 66:294-296
52. Jensen K (1991) Myopathy during treatment with fibrates and lovastatin. Ugeskr Laeger 153:862
53. Marais GE, Larson KK (1990) Rhabdomyolysis and acute renal failure induced by combination Iovastatin and gemfibrozil therapy. Ann Intern Med 112:228-230
54. Martinez-Garcia FA, Martin-Fernandez J, Molto JM, Villaverde R, Morales A, Fernandez-Barreiro A (1997) Myopathy caused by inhibitors of hydroxymethylglutarylcoenzyme A reductase. Rev Neurol 25:869-871
55. Iliadis EA, Rosenson RS (1999) Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia. Clin Cardiol 22:25-28
56. Wiklund O, Angelin B, Bergman M et al. (1993) Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med 94:13-20
57. Federman DG, Hussain F, Walters AB (2001) Fatal rhabdomyolysis caused by lipid-lowering therapy. South Med J 94:1023-1026
58. Tal A, Rajeshawari M, Isley W (1997) Rhabdomyolysis associated with simvastatin-gemfibrozil therapy. South Med J 90:546-547
59. Grunden JW, Fisher KA (1997) Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin. Ann Pharmacother 31:859-863
60. Bielecki JW, Schraner C, Briner V, Kuhn M (1999) Rhabdomyolysis and cholestatic hepatitis under treatment with simvastatin and Chlorzoxazone. Schweiz Med Wochenschr 129:514-518
61. Dresser GK, Spence JD, Bailey DG (2000) Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 38:41-57
62. Landesman KA, Stozek M, Freeman NJ (1999) Rhabdomyolysis associated with the combined use of hydroxymethylglutaryl-coenzyme A reductase inhibitors with gemfibrozil and macrolide antibiotics. Conn Med 63:455-457
63. Lee AJ, Maddix DS (2001) Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin. Ann Pharmacother 35:26-31
64. Kusus M, Stapleton DD, Lertora JJ, Simon EE, Dreisbach AW (2000) Rhabdomyolysis and acute renal failure in a cardiac transplant recipient due to multiple drug interactions. Am J Med Sci 320:394-397
65. Peces R, Pobes A (2001) Rhabdomyolysis associated with concurrent use of simvastatin and diltiazem. Nephron 89:117-118
66. Wong PW, Dillard TA, Kroenke K (1998) Multiple organ toxicity from addition of erythromycin to long-term lovastatin therapy. South Med J 91:202-205
67. Ramachandran S, Giles PD, Hartland A (1997) Acute renal failure due to rhabdomyolysis in presence of concurrent ciprofibrate and ibuprofen treatment. Br Med J 314:1593
68. Horn M (1996) Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals. Arch Dermatol 132:1254
69. Neuvonen PJ, Jalava KM (1996) Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 60:54-61
70. Gilad R, Lampl Y (1999) Rhabdomyolysis induced by simvastatin and ketoconazole treatment. Clin Neuropharmacol 22:295-297
71. Schmassmann-Suhijar D, Bullingham R, Gasser R, Schmutz J, Haefeli WE (1998) Rhabdomyolysis due to interaction of simvastatin with mibefradil. Lancet 351:1929-1930
72. Wombolt DG, Jackson A, Punn R, Smith S, McCune TR, Williams PB (1999) Case report: rhabdomyolysis induced by mibefradil in a patient treated with cyclosporine and simvastatin. J Clin Pharmacol 39:310-312
73. Jacobson RH, Wang P, Glueck CJ (1997) Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone. JAMA 277:296-297
74. Hill MD, Bilbao JM (1999) Case of the month: February 1999-54 year old man with severe muscle weakness. Brain Pathol 9:607-608
75. Blain H, Klein M, Weryha G, Trechot P, Hanesse B, Leclere J (1996) Rhabdomyolysis and unexplained malaise. Role of combination of ciprofibrate and norfloxacin. Rev Med Interne 17:859-860
76. Giner V, Munoz R, Redon J (2002) Risperidone and severe cerivastatin-induced rhabdomyolysis. J Intern Med 251:177-178
77. Gutierrez CA (2001) Sildenafil-simvastatin interaction: possible cause of rhabdomyolysis? Am Fam Physician 63:636-637
78. Caldwell SH, Hespenheide EE, von Borstel RW (2001) Myositis, microvesicular hepatitis, and progression to cirrhosis from troglitazone added to simvastatin. Dig Dis Sci 46:376-378
79. Mogyorosi A, Bradley B, Showalter A, Schubert ML (1999) Rhabdomyolysis and acute renal failure due to combination therapy with simvastatin and warfarin. J Intern Med 246:599-602